Amicus Therapeutics, Inc. (NASDAQ:FOLD) – Research analysts at Leerink Swann reduced their FY2017 earnings per share (EPS) estimates for Amicus Therapeutics in a report released on Wednesday. Leerink Swann analyst J. Schwartz now forecasts that the biopharmaceutical company will post earnings per share of ($1.77) for the year, down from their prior estimate of ($1.31). Leerink Swann currently has a “Buy” rating and a $20.00 price target on the stock. Leerink Swann also issued estimates for Amicus Therapeutics’ Q4 2017 earnings at ($0.34) EPS, FY2018 earnings at ($1.24) EPS, FY2019 earnings at ($0.91) EPS and FY2020 earnings at ($0.71) EPS.
Several other analysts have also recently commented on FOLD. BidaskClub upgraded shares of Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, July 19th. Zacks Investment Research upgraded shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 19th. J P Morgan Chase & Co reiterated an “overweight” rating and issued a $15.00 price target (up previously from $13.00) on shares of Amicus Therapeutics in a research note on Wednesday, August 9th. Chardan Capital boosted their price target on shares of Amicus Therapeutics from $12.50 to $17.50 and gave the stock a “buy” rating in a research note on Thursday, August 10th. Finally, Cowen and Company reiterated a “buy” rating and issued a $16.00 price target on shares of Amicus Therapeutics in a research note on Monday, August 14th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Amicus Therapeutics presently has an average rating of “Buy” and a consensus target price of $17.81.
COPYRIGHT VIOLATION NOTICE: “Equities Analysts Set Expectations for Amicus Therapeutics, Inc.’s FY2017 Earnings (FOLD)” was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://sportsperspectives.com/2017/11/15/equities-analysts-set-expectations-for-amicus-therapeutics-inc-s-fy2017-earnings-fold.html.
Shares of Amicus Therapeutics (NASDAQ FOLD) opened at $12.56 on Monday. Amicus Therapeutics has a one year low of $4.41 and a one year high of $16.60. The company has a quick ratio of 6.22, a current ratio of 6.32 and a debt-to-equity ratio of 0.39.
Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.10). The firm had revenue of $10.90 million during the quarter, compared to the consensus estimate of $9.02 million. Amicus Therapeutics had a negative return on equity of 63.54% and a negative net margin of 1,092.37%. The company’s quarterly revenue was up 419.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.33) EPS.
In other news, SVP Daphne Quimi sold 7,000 shares of the company’s stock in a transaction dated Thursday, October 12th. The shares were sold at an average price of $14.25, for a total transaction of $99,750.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Hung Do sold 50,194 shares of the company’s stock in a transaction dated Thursday, October 12th. The shares were sold at an average price of $14.25, for a total transaction of $715,264.50. The disclosure for this sale can be found here. Insiders have sold a total of 628,224 shares of company stock worth $9,024,003 over the last 90 days. Corporate insiders own 3.40% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Cubist Systematic Strategies LLC purchased a new stake in shares of Amicus Therapeutics during the 3rd quarter valued at about $231,000. Crestline Management LP bought a new position in Amicus Therapeutics during the 3rd quarter valued at about $797,000. Perceptive Advisors LLC grew its holdings in Amicus Therapeutics by 3.4% during the 3rd quarter. Perceptive Advisors LLC now owns 17,888,597 shares of the biopharmaceutical company’s stock valued at $269,760,000 after purchasing an additional 591,925 shares during the last quarter. Janus Henderson Group PLC grew its holdings in Amicus Therapeutics by 5.8% during the 3rd quarter. Janus Henderson Group PLC now owns 7,434,314 shares of the biopharmaceutical company’s stock valued at $112,109,000 after purchasing an additional 407,304 shares during the last quarter. Finally, Cowen Inc. grew its holdings in Amicus Therapeutics by 1,436.4% during the 3rd quarter. Cowen Inc. now owns 147,000 shares of the biopharmaceutical company’s stock valued at $2,217,000 after purchasing an additional 158,000 shares during the last quarter.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.